GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British ...

GSK's BCMA-directed antibody-drug conjugate Blenrep reduced the risk of death by 42% in a multiple myeloma trial that the company believes could be practice-changing. The DREAMM-7 study showed ...

Blenrep, which is predicted by analysts to produce revenues of around $1.5bn in 2026, is an antibody-drug conjugate that works by targeting B-cell maturation antigen (BCMA), a protein commonly ...

British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the risk of death by 42% in multiple myeloma, a common type of blood cancer, at ...

The Blenrep comeback continues for GSK. The blood cancer treatment, which was once pulled off the market, was found to help patients live longer in a Phase 3 clinical trial, the results of which were ...

Clinical trial investigators and the company believe these results could support making the GSK drug, Blenrep, a new standard of care treatment for this type of blood cancer. The new trial results ...

Belantamab mafodotin is under clinical development by GSK and currently in Phase I for Systemic Lupus Erythematosus.

GSK’s antibody-drug conjugate Blenrep looked like a breakthrough in multiple myeloma when it was approved in 2020, even as a fifth-line treatment for the difficult blood cancer. Just two years ...

Patients with relapsed/refractory multiple myeloma experienced significant improvements in overall survival (OS) when treated with Blenrep (belantamab mafodotin) in combination with Velcade ...